1 MG | x |
Save $ 6.00 |
$ 118.00
|
10 MG | x |
Save $ 49.00 |
$ 939.00
|
Chemical Properties of 'Bosutinib' |
|
CAT No. : |
CS-T-07791 |
CAS Registry No. : | 380843-75-4 |
Category : | API Standards |
Molecular Weight: | 530.45 |
Molecular Formula : | C₂₆H₂₉Cl₂N₅O₃ |
OTHER INFORMATION of 'Bosutinib' |
|
Therapeutic : | Anti-Cancer / Oncology |
Therapeutic : | Anti-Cancer / Oncology |
IUPAC Name : | 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile |
Applicationnotes : | "A novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. " |
Synonym : | Not available |
References : | "Bjorge, J,, et al,: J, Biol, Chem,, 275, 41439" |
Smileys : | ClC1=CC(Cl)=C(OC)C=C1NC(C2=C3C=C(OCCCN4CCN(C)CC4)C(OC)=C2)=C(C=N3)C#N |
Use Classification : | Human drugs -> Bosulif -> EMA Drug Category |
EC Number : | 700-455-1 |
UNII : | 5018V4AEZ0 |
NCI Thesaurus Code : | C60809 |
RXCUI : | 1307619 |
MeSH Entry Terms : | bosutinib |
Other Synonyms : | Bosutinib |
Removed Synonyms : | bosutinib hydrate |
Metabolite Pathways : | Bosutinib Inhibition of BCR-ABL |
Toxicity Summary : | Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue. Because bosutinib is not an inhibitor of c-KIT or PDGF receptor, it has less hematologic toxicities. |
Hepatotoxicity : | In large clinical trials of bosutinib, elevations in serum aminotransferase levels were common, occurring in up to 58% of bosutinib treated patients. Values greater than 5 times the upper limit of normal (ULN) occurred in 4% to 19% of bosutinib recipients (and 3% of imatinib treated subjects). These abnormalities were usually asymptomatic, but led to discontinuation of therapy in up to 2% of treated patients. In addition, there have been isolated reports of clinically apparent liver injury attributed to bosutinib therapy, although the frequency of this outcome and the clinical features of the injury have not been well defined. The time to onset has generally been within 3 months and the pattern of serum enzyme elevations was usually hepatocellular. |
Protein Binding : | 94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent. |
Exact Mass : | 529.1647452 |
InChI : | InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31) |
InchIKey : | UBPYILGKFZZVDX-UHFFFAOYSA-N |
Canonical SMILES : | CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC |
Isomeric SMILES : | CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC |
Product Description : | Bosutinib is an aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a nitrile, a N-methylpiperazine, an aromatic ether, a tertiary amino compound, an aminoquinoline and a dichlorobenzene. |
Custom Duty : | Applicable |
Port of Loading : | Canada |
Expected Dispatch : | 15-Aug-2022 |
Taxes : | Not Applicable |
Refund Policy : | 30-days money back |
Custom Duty : | Applicable |
Port of Loading : | Canada |
Expected Dispatch : | 15-Aug-2022 |
Taxes : | Not Applicable |
Refund Policy : | 30-days money back |
Looking for a discounted price or need more info for 'Bosutinib (CS-T-07791)' ?
If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.